Posted by Michael Wonder on 03 Jul 2020
MetVital announces FDA fast track designation of anhydrous enol-oxaloacetate for the treatment of patients with newly diagnosed glioblastoma multiforme
1 July 2020 - MetVital today announces that the U.S. FDA has notified MetVital that its lead drug candidate, "Anhydrous enol-oxaloacetate received fast track designation for the treatment of patients with newly diagnosed glioblastoma multiforme.
Anhydrous enol-oxaloacetate, a patented molecule, is MetVital's lead clinical development candidate for treatment of glioblastoma multiforme, a malicious type of brain cancer.
